Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Summary: Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urge...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Michael D. Nyquist, Alexandra Corella, Ilsa Coleman, Navonil De Sarkar, Arja Kaipainen, Gavin Ha, Roman Gulati, Lisa Ang, Payel Chatterjee, Jared Lucas, Colin Pritchard, Gail Risbridger, John Isaacs, Bruce Montgomery, Colm Morrissey, Eva Corey, Peter S. Nelson
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2020-05-01
سلاسل:	Cell Reports
الموضوعات:	prostate cancer androgen receptor TP53 RB1 plasticity antiandrogen
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2211124720306227
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!